Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minetta C Liu

Showing results (141-150 of 159) with videos related to

Pageof 16
Sort By:
Breast Cancer Research and Treatment|December 27, 2011
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)Laura J Esserman, Donald A Berry, Maggie C U Cheang, et al.
Cancer Cell|May 27, 2022
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapiesDenise M Wolf, Christina Yau, Julia Wulfkuhle, et al.
International Journal of Radiation Oncology, Biology, Physics|September 19, 2024
Dose Deintensified 3-Day Photon, Proton, or Brachytherapy: A Nonrandomized Controlled Partial Breast Irradiation TrialRobert W Mutter, Michael A Golafshar, Matthew R Buras, et al.
Nature Communications|February 26, 2026
Tumor-informed circulating tumor DNA stratifies recurrence risk and survival in anal squamous cell carcinomaPaul B Romesser, Aron Bercz, Janet Alvarez, et al.
Annals of Surgery|August 7, 2025
Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon CancerStacey A Cohen, Vasily N Aushev, George Laliotis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Neoadjuvant Model Is Still the Future for Drug Development in Breast CancerAngela DeMichele, Douglas Yee, Donald A Berry, et al.
JAMA Oncology|February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialRita Nanda, Minetta C Liu, Christina Yau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2025
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled AnalysisWolfgang Janni, Thomas W P Friedl, Tracy C Yab, et al.
Cancer Cell|November 18, 2022
Evaluation of cell-free DNA approaches for multi-cancer early detectionArash Jamshidi, Minetta C Liu, Eric A Klein, et al.
The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Neratinib in Early Breast CancerJohn W Park, Minetta C Liu, Douglas Yee, et al.
Pageof 16

Showing results (141-150 of 159) with videos related to

Sort By:
Pageof 16
Breast Cancer Research and Treatment|December 27, 2011
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)Laura J Esserman, Donald A Berry, Maggie C U Cheang, et al.
Cancer Cell|May 27, 2022
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapiesDenise M Wolf, Christina Yau, Julia Wulfkuhle, et al.
International Journal of Radiation Oncology, Biology, Physics|September 19, 2024
Dose Deintensified 3-Day Photon, Proton, or Brachytherapy: A Nonrandomized Controlled Partial Breast Irradiation TrialRobert W Mutter, Michael A Golafshar, Matthew R Buras, et al.
Nature Communications|February 26, 2026
Tumor-informed circulating tumor DNA stratifies recurrence risk and survival in anal squamous cell carcinomaPaul B Romesser, Aron Bercz, Janet Alvarez, et al.
Annals of Surgery|August 7, 2025
Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon CancerStacey A Cohen, Vasily N Aushev, George Laliotis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Neoadjuvant Model Is Still the Future for Drug Development in Breast CancerAngela DeMichele, Douglas Yee, Donald A Berry, et al.
JAMA Oncology|February 14, 2020
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialRita Nanda, Minetta C Liu, Christina Yau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2025
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled AnalysisWolfgang Janni, Thomas W P Friedl, Tracy C Yab, et al.
Cancer Cell|November 18, 2022
Evaluation of cell-free DNA approaches for multi-cancer early detectionArash Jamshidi, Minetta C Liu, Eric A Klein, et al.
The New England Journal of Medicine|July 14, 2016
Adaptive Randomization of Neratinib in Early Breast CancerJohn W Park, Minetta C Liu, Douglas Yee, et al.
Pageof 16